EGFR and hepatocellular carcinoma: According to some preclinical studies, cetuximab alone or in combination can inhibit HCC cell proliferation.155–157 Nevertheless, in one phase II study, cetuximab therapy did not show encouraging results.158 One study explored the performance of a combination of the anti-EGFR antibody cetuximab with oxaliplatin and capecitabine in late-stage HCC and showed that the capecitabine/oxaliplatin/cetuximab combination was tolerable, although there was a high rate of diarrhea.